Medical devices, healthcare technology and the business of care
510(k) clearance · K262938

cobas eplex respiratory pathogen panel 3

GenMark Diagnostics, Inc. · Decision date Oct 30, 2026

MEDTECHLEDGER EXPLANATIONK262938

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on October 30, 2026 for K262938, the cobas eplex respiratory pathogen panel 3 submitted by GenMark Diagnostics, Inc. of Carlsbad, California. The submission was received August 21, 2026 and reviewed under 21 CFR 866.3981 in the Microbiology specialty, product code QOF, Class II. The listed predicate is the BioFire Respiratory Panel 2.1 (DEN200031). SESE denotes 510(k) clearance, not PMA approval.

The device is a multiplexed nucleic acid in vitro diagnostic test for use on the cobas eplex system, intended for simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs from individuals with signs and symptoms of respiratory tract infection. The summary describes competitive nucleic acid hybridization in a sandwich assay format with PCR and/or RT-PCR amplification. The source does not state the full intended-use wording, performance results or any clearance conditions beyond the decision record.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Oct 30, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262938
Regulatory pathway
510(k) premarket notification
Product code
QOF
Decision code
SESE
Decision date
Oct 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents.

Product code
QOF
FDA device class
2

FDA decision timeline

  1. K262938 received

    Application receipt date recorded by FDA.

  2. K262938 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QOF

Product / regulatory recordCompanyPathwayDecision dateSource
Cepheid510(k) clearanceOct 22, 2026FDA
Cepheid510(k) clearanceOct 2, 2026FDA
Cepheid510(k) clearanceSep 25, 2026FDA
Biofire Diagnostics510(k) clearanceSep 22, 2026FDA
Baebies, Inc.510(k) clearanceSep 11, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

GenMark Diagnostics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Carlsbad, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records